BioCentury
ARTICLE | Company News

Cara, Chong Kun Dang deal

May 7, 2012 7:00 AM UTC

Cara granted Chong Kun Dang exclusive rights in South Korea to develop and commercialize pain therapy CR845. Cara will receive an upfront payment, which includes an equity investment, and is eligible...